CSIMarket
 
Syros Pharmaceuticals Inc   (SYRS)
Other Ticker:  
 
 
Price: $6.0100 $-0.02 -0.332%
Day's High: $6.1985 Week Perf: -8.38 %
Day's Low: $ 5.98 30 Day Perf: -15.59 %
Volume (M): 222 52 Wk High: $ 8.17
Volume (M$): $ 1,337 52 Wk Avg: $4.18
Open: $6.01 52 Wk Low: $2.09



 Market Capitalization (Millions $) 168
 Shares Outstanding (Millions) 28
 Employees -
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -105
 Cash Flow (TTM) (Millions $) -59
 Capital Exp. (TTM) (Millions $) 1

Syros Pharmaceuticals Inc
Syros Pharmaceuticals Inc is a biopharmaceutical company focusing on developing gene control therapies for patients suffering from cancer and other diseases. They aim to target the underlying causes of these diseases by understanding the regulatory components of the genome and utilizing their proprietary gene control platform. Syros uses deep insights into genomic regulatory networks to identify and target specific genes that play a crucial role in controlling disease. Their goal is to pioneer a new wave of precision medicines that can effectively treat previously intractable diseases.


   Company Address: 35 CambridgePark Drive Cambridge 2140 MA
   Company Phone Number: 744-1340   Stock Exchange / Ticker: NASDAQ SYRS
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Business Update

Syros Pharmaceuticals Sets High 2024 Milestones for Tamibarotene Amid Financial Hurdles

Published Mon, Jan 8 2024 12:00 PM UTC

Syros Pharmaceuticals, a prominent biopharmaceutical company headquartered in Cambridge, Massachusetts, has recently released its anticipated milestones for the year 2024. As a leader in the development of innovative treatments for hematologic malignancies, Syros Pharmaceuticals is seizing the new year with zeal and renewed commitment towards the advancement of its promising...

Stock Transactions

Syros Pharmaceuticals Announces Pricing of $45 Million Underwritten Offering, Shares Surge 17.51% YTD

Published Tue, Dec 19 2023 12:27 PM UTC



Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to revolutionizing the treatment of hematologic malignancies, recently revealed the pricing details of its underwritten offering of common stock and pre-funded warrants. The offering, consisting of 4,939,591 shares of common stock and pre-funded warrants to purchase 5,242,588 shares, is expected t...

Product Service News

Tamibarotene Shows Promising Results in Phase 2 Clinical Trial for Acute Myeloid Leukemia, Boosting Syros Pharmaceuticals Amid Revenue Decline

Published Wed, Dec 6 2023 12:00 PM UTC


Syros Pharmaceuticals, a leading biopharmaceutical company focused on revolutionizing treatment options for hematologic malignancies, has recently released encouraging initial data from its ongoing SELECT-AML-1 Phase 2 clinical trial. The trial evaluates the efficacy of tamibarotene, an oral medication that acts as a selective retinoic acid receptor alpha (RAR) agonist,...

Syros Pharmaceuticals Inc

Hematologic Malignancy Revolution: Syros Pharmaceuticals Inc Faces Unique Challenges and Opportunities Amidst -3.315% Revenue Slide



Syros Pharmaceuticals Inc, a biopharmaceutical company focused on revolutionizing hematologic malignancy treatments, recently released its financial results for the most recent fiscal period. With both positive and negative indicators, the company faces unique challenges and opportunities. This article will examine the implications of the financial results on Syros Pharmaceuticals Inc and its potential trajectory moving forward.
Improving Losses, but Room for Growth:
In the most recent fiscal period, Syros Pharmaceuticals Inc showcased progress in controlling losses. The company's loss per share decreased from $-3.21 to $-1.43 compared to the previous year. Furthermore, the loss per share rose by $-0.13 from the previous quarter. Although these results demonstrate some positive momentum, it is crucial for Syros Pharmaceuticals to sustain this trend and work towards profitability.

Business Update

Syros Pharmaceuticals Releases Q3 2023 Financial Results and Charts Path for Future Growth

Published Tue, Nov 14 2023 12:30 PM UTC



Syros Pharmaceuticals, a leading biopharmaceutical company dedicated to revolutionizing the treatment of hematologic malignancies, recently disclosed its financial results for the third quarter ended September 30, 2023. The company also provided an overview of its current position and strategic plans for growth. Despite a decline in revenue that surpassed its compe...






 

Syros Pharmaceuticals Inc's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com